RETRACTION

MicroRNA-503 Inhibits Non-Small Cell Lung Cancer Progression by Targeting PDK1/PI3K/AKT Pathway [Retraction]

Wei Y, Liao Y, Deng Y, Zu Y, Zhao B, Li F. Onco Targets Ther. 2019;12:9005-9016.

We, the Editors and Publisher of OncoTargets and Therapy, have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figures 2, 5 and 7 with images from other unrelated articles. Specifically,

- The image for Figure 2B, PC9, NC inhibitor, has been duplicated with the image for Figure 2D, PANC1, Solasodine 10μg/mL, from Fan Y, Li Z, Wu L, et al. Solasodine, Isolated from Solanum sisymbriifolium Fruits, Has a Potent Anti-Tumor Activity Against Pancreatic Cancer. *Drug Des Devel Ther*. 2021;15:1509–1519. <u>https://doi.org/10.2147/DDDT.S266746</u>.
- Images for Figure 3A have been duplicated with images for Figure 4D from Wang M, Yu R, Ling X, et al. COPB2 promotes metastasis and inhibits apoptosis of lung adenocarcinoma cells through functioning as a target of miR-216a-3p JF. *Translational Cancer Research*. 2020; 9(4): 2648–2659. <u>https://doi.org/10.21037/tcr.2020.02.65</u> and Figure 5B from Jia Yy, Yu Y, Li HJ. POSTN promotes proliferation and epithelial-mesenchymal transition in renal cell carcinoma through ILK/AKT/mTOR pathway. *J Cancer*. 2021;12(14):4183–4195. <u>https://doi.org/10.7150/jca.51253</u>.
- The image for Figure 5C, A549, miR-503+PDK1, has been duplicated with the image for Figure 3C, NB4 cell, inhibitors, from Wang D, Chen J, Ding Y, et al. miR-188-5p Promotes Tumor Growth by Targeting CD2AP Through PI3K/AKT/mTOR Signaling in Children with Acute Promyelocytic Leukemia. *Onco Targets Ther.* 2020;13:6681–6697. https://doi.org/10.2147/OTT.S244813.

The authors did not respond to our queries and were unable to provide an explanation for the duplicated images or provide data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted'.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S453391

OncoTargets and Therapy 2023:16 1023

1023

© 2023 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).